All In Biotech

Drug Trial Radar · NCT05732155

Preliminary Effectiveness of Hybrid Individual and Group MDMA-assisted Therapy for War-related PTSD

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jun 1, 2023

Primary completion

Jun 1, 2027

Study completion Jul 1, 2028

Sponsor

Lead sponsor
Guy SchusheimAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Resilient Pharmaceuticals
First posted
Feb 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of this study is to use standard clinical measures to explore the safety and preliminary effectiveness of open-label MDMA-assisted therapy with a flexible dose of methylenedioxymethamphetaminel, in participants with war-related Post traumatic Stress Disorder, in a hybrid individual and group treatment protocol. The overall safety objective is to assess the severity, incidence, and frequency of AEs, AEs of Special Interest (AESIs), and Serious Adverse Events (SAEs), concomitant medication use, suicidal ideation and behavior and vital signs .

Conditions

  • Post Traumatic Stress Disorder
  • MDMA ('Ecstasy')

Interventions

  • methylenedioxymethamphetamineDrug

    Participants in the experimental arm receive MDMA hydrochloride during three approximately 8-hour experimental sessions conducted within a manualized MDMA-assisted therapy protocol. Two sessions are delivered individually and one is delivered in a group setting. Each session includes an initial dose of MDMA hydrochloride followed by a planned supplemental half-dose approximately two hours later, unless the participant declines or tolerability concerns arise. MDMA administration is embedded within preparatory and integration psychotherapy delivered according to the study protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from pre-treatment baseline to post-treatment in CAPS-5 total scoreTime frame: From baseline to V18, approximately 18 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Emek medical center

    Afula, Israel · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.